Press Releases

Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States

Regulated information
Inside information

Mont-Saint-Guibert, Belgium – 19 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the de...

Nyxoah Reports Full Year 2020 Results

Regulated information

Conference call and webcast today at 3pm CET / 9am ET Mont-Saint-Guibert, Belgium – 9 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “C...

Nyxoah to Delay Full Year 2020 Earnings Release Until April 9, 2021

Mont-Saint-Guibert, Belgium – 2 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the dev...

Nyxoah announces the publication of first positive clinical data in an OSA patient suffering from Complete Concentric Collapse (CCC)

Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions ...

Information on the total number of voting rights and shares

Transparancy release

Mont-Saint-Guibert (Belgium), 25 February 2021, 18:00h CET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings,...

Nyxoah to present at the Oppenheimer 31st Annual Healthcare Conference

Mont-Saint-Guibert, Belgium – 24th February 2021 – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the develop...

Nyxoah receives FDA approval for full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)

Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions ...

Nyxoah and Vanderbilt University enter exclusive licensing agreement regarding next generation neurostimulation technologies to treat Obstructive Sleep Apnea (OSA)

Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions ...

Nyxoah announces full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)

First US patient implanted in the DREAM pivotal IDE study, with the Genio® system for the treatment of Obstructive Sleep Apnea (OSA)

DREAM is a pivotal, Investigational Device Exemption (IDE) study, designed to support marketing authorization in the United States Nyxoah S.A. (EBR: NYXH)...

bubble
bubble
bubble
bubble
bubble